SCHEMBL8090286

SCHEMBL8090286

Cc1ccc(-c2cccc(C)n2)c(F)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 1/20 0.52
CCR8 P51685 1/20 0.52
TGFBR1 P36897 6/20 0.43
GRM2 Q14416 1/20 0.40
MAP3K5 Q99683 1/20 0.39
CYP2A6 P11509 1/20 0.39
METAP2 P50579 1/20 0.39
CYP1A2 P05177 1/20 0.37
GRM5 P41594 1/20 0.37
HCRTR1 O43613 1/20 0.37
HCRTR2 O43614 1/20 0.37
HSD17B10 Q99714 1/20 0.37
KDM1A O60341 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC11 Q96DB2 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
GHSR Q92847 1/20 0.36
ACHE P22303 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15888380 0.86 CCR1 (0.52) CCR1CCR8TGFBR1GRM5HCRTR1
SCHEMBL2615815 0.83 CCR1 (0.48) CCR1CCR8TGFBR1GRM2CYP1A2
SCHEMBL6618989 0.83 ASIC3 (0.42) GRM2MAP3K5
SCHEMBL25562475 0.81 CCR1 (0.56) CCR1CCR8TGFBR1CYP2A6METAP2
SCHEMBL8450245 0.79 CCR1 (0.58) CCR1CCR8TGFBR1CYP2A6METAP2
SCHEMBL995546 0.79 CCR1 (0.52) CCR1CCR8TGFBR1CYP2A6METAP2
SCHEMBL24224628 0.78 CCR1 (0.56) CCR1CCR8TGFBR1CYP2A6METAP2
SCHEMBL6622616 0.78 MAP3K5 (0.38) GRM2MAP3K5HSD17B10KDM1AHDAC1
SCHEMBL6622613 0.78 MAP3K5 (0.38) GRM2MAP3K5METAP2HSD17B10KDM1A
SCHEMBL16277390 0.77 SORT1 (0.55) CCR1CCR8TGFBR1GRM5HCRTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040229911-A1 New pharmaceutical combinations for NOS inhibitors PFIZER INC 2004-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040229911-A1 New pharmaceutical combinations for NOS inhibitors NOS1, NOS3, NPBWR1 CCR1 1520/4885CCR8 3120/4885TGFBR1 1420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.